Ampicillin-Gentamicin Synergy: Target Organism
Gentamicin combined with ampicillin provides synergistic bactericidal coverage primarily against Enterococcus species, specifically Enterococcus faecalis, E. faecium, and E. durans. 1
Primary Target: Enterococcal Species
The combination of ampicillin plus gentamicin is specifically designed to overcome the intrinsic resistance of enterococci to aminoglycosides when used alone. The FDA label explicitly states that "the combination of gentamicin and penicillin G has a synergistic bactericidal effect against strains of Enterococcus faecalis, E. faecium, and E. durans" and that "an enhanced killing effect against many of these strains has also been shown in vitro with combinations of gentamicin and ampicillin." 1
Clinical Context: Infective Endocarditis
This synergistic combination is most clinically relevant in the treatment of enterococcal infective endocarditis (IE). The 2015 American Heart Association guidelines recommend:
- Ampicillin or penicillin plus gentamicin for 4-6 weeks for native valve endocarditis caused by enterococci susceptible to both agents 2
- Six weeks of therapy for prosthetic valve endocarditis 2
- This combination is preferable to vancomycin-gentamicin due to superior in vitro activity, better performance in animal models, and reduced risk of nephrotoxicity and ototoxicity 2
Why This Combination Works
Gentamicin alone is not effective against enterococci because most enterococcal species (including E. faecalis, E. faecium, and E. durans) are intrinsically resistant to aminoglycosides. 1 However, when combined with a cell wall-active agent like ampicillin:
- Ampicillin disrupts the cell wall, allowing gentamicin to penetrate the bacterial cell
- This creates synergistic bactericidal activity that neither agent achieves alone 3, 4
- The combination is bactericidal against 100% of susceptible enterococcal strains at achievable serum concentrations 3
Important Caveats
High-Level Aminoglycoside Resistance
If the enterococcal strain demonstrates high-level gentamicin resistance (MIC >500 μg/mL), synergy is lost. In these cases:
- Use ampicillin plus ceftriaxone as an alternative double β-lactam regimen 2
- This applies to aminoglycoside-resistant enterococcal strains where gentamicin synergy testing is negative
Other Organisms with Synergy
While enterococci are the primary target, ampicillin-gentamicin synergy has also been documented against:
- Viridans group streptococci with penicillin MIC ≥0.5 μg/mL 2
- Listeria monocytogenes (bactericidal synergy demonstrated in vitro) 5
However, these are secondary applications; the classic indication remains enterococcal infections, particularly endocarditis.
What Gentamicin Does NOT Cover with Synergy
The FDA label explicitly states that most streptococcal species (including S. pneumoniae and Group D streptococci other than enterococci) and anaerobic organisms (Bacteroides, Clostridium) remain resistant even with combination therapy. 1